home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630147.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
35 lines
Document 0147
DOCN M9630147
TI In-vitro and intracellular activity of rifabutin on drug-susceptible and
multiple drug-resistant (MDR) tubercle bacilli.
DT 9603
AU Luna-Herrera J; Reddy MV; Gangadharam PR; Department of Medicine,
University of Illinois at Chicago 60612,; USA.
SO J Antimicrob Chemother. 1995 Aug;36(2):355-63. Unique Identifier :
AIDSLINE MED/96052020
AB Rifabutin, a spiropiperidyl derivative of rifampicin, is approved for
the prophylaxis of Mycobacterium avium infections in AIDS patients in
the US, and for the treatment of M. avium infections, tuberculosis and
multiple drug resistant tuberculosis in many countries. In the present
study, rifabutin was compared with rifampicin for its activity against
drug susceptible and multi-drug resistant tubercle bacilli by several
in-vitro and macrophage studies. Rifabutin exhibited similar or greater
in-vitro activity than rifampicin as judged by the minimal inhibitory
concentration (MIC), minimal bactericidal concentration (MBC) and
MBC/MIC ratios, as well as continuous exposure and post-antibiotic
effect studies. Rifabutin has been shown to be active against some
multiple drug resistant strains which were resistant to rifampicin. In
macrophage studies with continuous exposure to the drug or when the drug
had been removed after 24 h, rifabutin also demonstrated high activity
which was better than RMP against intracellular tubercle bacilli. This
long-acting intracellular anti-mycobacterial activity may explain, in
part, the clinical efficacy of rifabutin.
DE Antibiotics, Antitubercular/*PHARMACOLOGY *Drug Resistance, Multiple
Human In Vitro Macrophages/MICROBIOLOGY Microbial Sensitivity Tests
Mycobacterium tuberculosis/*DRUG EFFECTS Rifabutin/*PHARMACOLOGY
Rifampin/PHARMACOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).